Back
Also listed as
GSK
NYSE
Day Range
$26.13
$30.15
52-Week Range
$15.54
$31.48
Volume
507
50D / 200D Avg
$27.21
/
$22.53
Prev Close
$26.08
Price History
Financial Trends
Peer Comparison
vs Healthcare sector median (626 peers)
| Metric | Stock | Sector Median |
|---|---|---|
| P/E | 18.3 | 0.4 |
| P/B | 6.4 | 2.9 |
| ROE % | 38.0 | 3.8 |
| Net Margin % | 17.5 | 3.9 |
| Rev Growth 5Y % | -1.1 | 10.0 |
| D/E | 1.1 | 0.2 |
Key Takeaways
Revenue declined -1.08% annually over 5 years
Earnings grew 121.94% over the past year
ROE of 38.04% indicates high profitability
Net margin of 17.50% shows strong profitability
Generating 5.95B in free cash flow
PEG of 0.10 suggests growth is underpriced
Growth
Revenue Growth (5Y)
-1.08%
Revenue (1Y)4.10%
Earnings (1Y)121.94%
FCF Growth (3Y)16.01%
Quality
Return on Equity
38.04%
ROIC15.77%
Net Margin17.50%
Op. Margin21.95%
Safety
Debt / Equity
1.08
Current Ratio0.82
Interest Coverage10.23
Valuation
P/E Ratio
18.30
P/B Ratio6.39
EV/EBITDA16.59
Dividend Yield0.03%
All Fundamental Metrics
| Growth | |||
| Revenue Growth (1Y) | 4.10% | Revenue Growth (3Y) | 3.78% |
| Earnings Growth (1Y) | 121.94% | Earnings Growth (3Y) | 7.69% |
| Revenue Growth (5Y) | -1.08% | Earnings Growth (5Y) | 6.85% |
| Profitability | |||
| Revenue (TTM) | 32.66B | Net Income (TTM) | 5.72B |
| ROE | 38.04% | ROA | 9.35% |
| Gross Margin | 72.54% | Operating Margin | 21.95% |
| Net Margin | 17.50% | Free Cash Flow (TTM) | 5.95B |
| ROIC | 15.77% | FCF Growth (3Y) | 16.01% |
| Safety | |||
| Debt / Equity | 1.08 | Current Ratio | 0.82 |
| Interest Coverage | 10.23 | Dividend Yield | 0.03% |
| Valuation | |||
| P/E Ratio | 18.30 | P/B Ratio | 6.39 |
| P/S Ratio | 3.20 | PEG Ratio | 0.10 |
| EV/EBITDA | 16.59 | Dividend Yield | 0.03% |
| Market Cap | 104.58B | Enterprise Value | 118.90B |
Income Statement
Annual, most recent first
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 32.66B | 31.38B | 30.33B | 29.32B | 34.11B |
| Net Income | 5.72B | 2.58B | 4.93B | 14.96B | 4.39B |
| EPS (Diluted) | 1.39 | 0.62 | 1.20 | 3.66 | 1.35 |
| Gross Profit | 23.69B | 22.33B | 21.76B | 19.77B | 22.51B |
| Operating Income | 7.17B | 4.02B | 6.75B | 6.43B | 6.20B |
Balance Sheet
Annual, most recent first
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Total Assets | 61.11B | 59.46B | 59.01B | 60.15B | 79.10B |
| Total Liabilities | 45.09B | 46.38B | 46.21B | 50.05B | 57.76B |
| Shareholders' Equity | 16.37B | 13.67B | 13.35B | 10.60B | 15.06B |
| Total Debt | 17.72B | 16.99B | 18.02B | 20.99B | 24.17B |
| Cash & Equivalents | 3.40B | 3.69B | 2.94B | 3.72B | 4.27B |
| Current Assets | 17.51B | 17.00B | 18.64B | 20.77B | 18.67B |
| Current Liabilities | 21.39B | 21.70B | 21.07B | 22.81B | 23.67B |